Fire Capital Management LLC Purchases Shares of 4,524 Novo Nordisk A/S (NYSE:NVO)

Fire Capital Management LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,524 shares of the company's stock, valued at approximately $389,000.

Several other hedge funds have also made changes to their positions in NVO. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its position in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NVO. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Stock Up 2.8%

NYSE:NVO traded up $1.94 during mid-day trading on Friday, hitting $71.40. The stock had a trading volume of 11,185,051 shares, compared to its average volume of 6,800,832. The stock has a 50-day simple moving average of $65.58 and a two-hundred day simple moving average of $81.59. The company has a market capitalization of $320.41 billion, a PE ratio of 21.70, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.